The market for mHealth data aggregation platforms has become increasingly congested over the past year, with Apple and Google joining the more healthcare industry-focused Validic. Now Vivametrica has joined the space, outlining plans for a platform that fixes the inconsistencies in data from consumer mHealth products and combines them with outputs from medical devices.
The Harvard Medical School professor has long advocated for greater openness, with the sharing of his own data through the Personal Genome Project a standout example
With pharma trade groups now committed to publishing the synopses of clinical study reports for some drugs, big-name consortium TransCelerate BioPharma has published a guide on how to redact documents.
Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.
Less than one year has passed since a $760,000, Mark Cuban-backed seed round put Validic on the map, but the firm and its health data aggregation platform have come a long way in the intervening months. And with Validic's scale and ambition growing, the company has raised $5 million in first round funding.
Over the past year, many tech heavyweights have begun moving into the mHealth sector. Developers got an early look at Google's offering this week, with the search giant releasing a preview version of its APIs for health app developers.
Amid all the controversies generated by the big neuroscience initiatives getting underway on either side of the Atlantic, areas of common ground such as the need to standardize and share data have emerged. Now, a group of U.S. research institutions have teamed up to establish a unified data format to facilitate the sharing of information.
With IT playing a bigger and bigger role across the R&D process, market research shop Grand View Research has tipped the computational biology market to achieve a compound annual growth rate (CAGR) of 21.1% over the next six years. And that trajectory will result in the value of the sector topping $4.2 billion by 2020.
Over the first few months of 2014, Novartis quietly began laying off workers, shedding an estimated 3,000 jobs in four months. Now BioSpace has provided details of where the ax has fallen and why, with development IT teams suffering heavy job losses.
Two hundred eighty scientists have signed an open letter threatening to boycott Europe's Human Brain Project. The scientists have fundamental concerns about exactly what Europe is trying to achieve with its €1 billion ($1.4 billion) budget.